tbuckley/cabot-search huggingface dataset:
Pulse Pressure Amplification
Authors: Athanase Benetos, Frédérique Thomas, Laure Joly, Jacques Blacher, Bruno Pannier, Carlos Labat, Paolo Salvi, Harold Smulyan, Michel E. Safar
Journal: Journal of the American College of Cardiology (2010)

The aim of this study was to determine whether the carotid/brachial (C/B) ratio is an independent predictor of cardiovascular (CV) risk. Brachial and carotid pulse pressure (PP) are independent predictors of CV risk, mainly in elderly patients. Because PP is physiologically lower at the brachial than at the carotid arterial site, PP amplification is represented by the C/B ratio and could independently predict CV risk. In a Paris population (n = 834), brachial and carotid PP were measured from sphygmomanometry and pulse wave analysis. With stepwise multiple regression, carotid PP was calculated from a nomogram including age, sex, body height, brachial PP, and plasma glucose. This model was applied to 125,151 subjects, followed for 12 years, during which 3,997 deaths occurred (735 of CV origin). With Cox regression analysis, multi-adjusted hazard ratios (HRs) were calculated for 1 SD increase of brachial PP, calculated carotid PP, and C/B ratio. Brachial PP was significantly associated with both CV and all-cause mortality (HR: 1.16, 95% confidence interval [CI]: 1.13 to 1.19, and HR: 1.13, 95% CI: 1.10 to 1.17, respectively). Calculated carotid PP predicted a similar risk (HR: 1.21, 95% CI: 1.15 to 1.28, and HR: 1.18, 95% CI: 1.12 to 1.25, respectively). Finally, the C/B ratio was a strong risk predictor (HR: 1.22, 95% CI: 1.12 to 1.32, and HR: 1.41, 95% CI: 1.14 to 1.73, respectively). Addition of drug treatment and other confounding variables did not statistically modify the results. Brachial PP, calculated carotid PP, and C/B PP amplification all predict CV mortality. In contrast to brachial and carotid PP, the C/B ratio is less dependent on blood pressure calibration and thus can be directly applicable to large population studies.
SP0046 Pluripotent fibroblasts in rheumatoid arthritis
Authors: E. Neumann, U. Müller-Ladner
Journal: Annals of the Rheumatic Diseases (2013)

Rheumatoid arthritis (RA) is characterized by chronic inflammation, synovial hyperplasia and progressive joint destruction. Rheumatoid arthritis synovial fibroblasts (RA-SF) are central effector cells in cartilage erosion and contribute actively to inflammation. RA-SF show an activated phenotype that is independent of the inflammatory environment. Although new aspects regarding RA-SF activation <i>via</i> TLR activation, inflammatory factors, matrix degradation products and others have been uncovered, the primarily pathophysiological processes in early arthritis leading to permanent activation are mostly unknown. New findings of RA-SF activation that contribute to their altered behaviour resulting in matrix destruction and inflammation as well as their increased migratory potential in RA will be summarized. <h3>Disclosure of Interest</h3> None Declared
Conformable metallic stent placement in a sigmoid volvulus: a feasible and effective bridge option
Authors: R. Di Mitri, F. Mocciaro, S. Morini, M. Provenzano, A. Marino
Journal: Endoscopy (2013)

Sigmoid volvulus is the third leading cause of colonic obstruction in adults. Surgical resection with primary anastomosis is the standard of care [1]. Endoscopic reduction is a feasible option in patients with uncomplicated conditions [2] despite the fact that mechanical detorsion is not always successful, even by skilled hands. Few data are available concerning the role of self-expanding metallic stents (SEMS) in the treatment of benign colorectal strictures, including sigmoid volvulus.
TCT-340 Efficacy and Safety of Biodegradable Polymer Biolimus-Eluting Stents versus Durable Polymer Everolimus-Eluting Stents in Diabetic Patients - A Prospective Non-Randomized Single Center Long Term Comparison
Authors: Pierre Sprimont, Christophe de Meester, Jean Renkin, Olivier Gurne, Joelle Kefer, Patrick Chenu, Jean Louis Vanoverschelde, Nadia Debbas
Journal: Journal of the American College of Cardiology (2012)
460 IMPACT OF SEVERE HEPATITIS REACTIVATION ON THE KINETICS OF HEPATITIS B SURFACE ANTIGEN LEVELS IN HEPATITIS B E ANTIGEN (HBEAG)-NEGATIVE CHRONIC HEPATITIS B
Authors: H.L.Y. Chan, G.L. Wong, A.O. Lo, A.M. Chiim, H.-Y. Chan, K.K. Yiu, S.H. Chu, V.W. Wong
Journal: Journal of Hepatology (2012)
SAT0465 The Myositis Disease Activity Assessment Tool and the Printo Criteria for Clinically Inactive Disease Applied after Long-Term Follow-Up in Juvenile Onset Dermatomyositis.
Authors: H. Sanner, I. Sjaastad, B. Flatø
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> There is limited knowledge about persistent disease activity and frequency of inactive disease in Juvenile Dermatomyositis (JDM) patients after long-term follow-up. <h3>Objectives</h3> To apply the Myositis Disease Activity Assessment Tool (MDAAT) and Pediatric Rheumatology International Trials Organization (PRINTO) criteria for inactive disease in JDM patients after long-term follow-up, and to examine associations between clinically inactive disease, MDAAT, and other validated disease activity measures. <h3>Methods</h3> Inclusion criteria were probable or definitive Dermatomyositis (Bohan/Peter criteria), disease onset before 18 years and minimum 2 years disease duration. A retrospective inception cohort of 60 JDM patients (60% female) was clinically examined median 16.8 years (range 2–38 years) after disease onset. The cohort was divided in patients with inactive (JDM-inactive) and active disease (JDM-active) by the PRINTO criteria; at least three of four of: CK≤150, Child Myositis Assessment Scale (CMAS) ≥ 48, Manual Muscle Test (MMT) ≥ 78 and physician global disease activity (PhyGloVAS) ≤ 0.2. Disease activity was also measured by MDAAT (Myositis Intention-to-Treat Activity Index (MITAX) and the Myositis Disease Activity Assessment Visual Analog Scales (MYOACT)), Disease Activity Score (DAS), patient/parent overall disease activity (PtsGloVAS) and child-HAQ/HAQ. <h3>Results</h3> Thirty patients (50%) had inactive disease (15 female); disease duration in JDM-active and JDM-inactive were comparable. All variables included in the PRINTO composite score for inactive disease clearly differed between the two groups (P`s &lt; 0.001), except for CK which was similar (P=0.660). At follow-up, 18/60 (30%) used at least one anti-inflammatory drug; 14 of these were JDM-active. Of JDM-inactive patients, 4/30 patients were inactive <i>on</i> medication and 26/30 inactive <i>off</i> medication. By MYOACT, disease activity was most common in the skin (58%), skeletal (28%) and constitutional and muscle domains (both 18%). MYOACT global and MYOACT extramuscular both showed a strong correlation with DAS and PhyGloVAS (r<sub>s</sub>`s ≥ 0.85) and a moderate correlation with PtsGloVAS, CMAS, MMT, and CHAQ/HAQ (r<sub>s</sub>`s 0.32-0.49). <h3>Conclusions</h3> Median 16.8 years after disease onset, 50% of JDM patients had clinically inactive disease which was highly associated with low disease activity measured by MDAAT and DAS. <h3>Disclosure of Interest</h3> None Declared
AB0211 Sarcopenia in patients with inflammatory arthritis
Authors: D. Fitzpatrick, A. McPartland, B. Mcgowan, C. Silke, B. Whelan
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Sarcopenia is the progressive generalised loss of skeletal muscle and strength related to age and disease activity and is defined by appendicular skeletal mass/height squared (ASM/h<sup>2</sup>). Sarcopenia is common in inflammatory arthritis<sup>1</sup> and has been linked with functional disability<sup>2</sup> <h3>Objectives</h3> The aim of this study was to assess the relationship between ASM/h<sup>2</sup> and physical activity, fatigue, pain, and disability in inflammatory arthritis patients. <h3>Methods</h3> Patients with inflammatory arthritis attending the NWRU were invited to take part in the study which involved the use of whole body DXA, FACIT-F and IPAQ questionnaires, HAQ-DI and routine bloods. <h3>Results</h3> There were 11 patients in the cohort with a mean age of 67.4 and mean disease duration of 17 years. A positive correlation existed between ASM/height<sup>2</sup> and physical activity (R=.714, p=.047). There was a negative correlation between VAS Pain and physical wellbeing (R=.-764, p=.010), functional wellbeing (R= -.828, p=.003), FACIT-fatigue (R= -.634, p=.049) and a positive correlation between VAS Pain and the HAQ-DI (R=.732, p=.025). VAS Fatigue correlated negatively with physical wellbeing (R= -.752, p=.012) and positively with HAQ-DI (R=.621, p=.044). No significant correlation was found between ASM/height<sup>2</sup> and HAQ-DI or fatigue. <h3>Conclusions</h3> As expected, ASM/h<sup>2</sup> is correlated with physical activity but somewhat surprisingly not with fatigue or functional ability. The numbers of subjects included is very low and as such all findings will have to be confirmed as more subjects are added to the study. <h3>References</h3> Giles J, Ling S, Ferrucci L. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. <i>Arthritis Care &amp;amp;</i> 2008. Available at: http://onlinelibrary.wiley.com/doi/10.1002/art.23719/full. Accessed June 29, 2012. Janssen I, Heymsfield S. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. <i>Journal of the American</i>. 2002:889-896. Available at: http://onlinelibrary.wiley.com/doi/10.1046/j.1532-5415.2002.50216.x/full. Accessed June 29, 2012. <h3>Disclosure of Interest</h3> None Declared
Abstract LB-513: Abelson Interactor 1 is a novel substrate of protein kinase D2: potential implications in tumor cell migration
Authors: Subbaiah Chary Nimmagadda, Tim Eiseler, Johan Van Lint, Peter Storz, Thomas Seufferlein
Journal: Cancer Research (2012)

Abstract Introduction and Objective: The serine/threonine kinases of the protein kinase D family (PKCmu/PKD1, PKD2, PKCnu/PKD3), a subfamily of the CAMK superfamily, have been implicated in regulation of multiple biological processes including proliferation, survival, apoptosis, angiogenesis and motility. The precise mechanisms by which the three PKDs modulate these processes are incompletely understood and require a better knowledge of their signaling context. Methodology and Results: Using the ProtoArray Human Protein Microarray v4.0 (Invitrogen), we identified Abelson interactor 1 (ABI1) as a novel PKD2 substrate. ABI1 was first identified as the downstream target of Abl tyrosine kinase and is an adaptor protein involved in actin reorganization and lamellipodia formation along with WAVE2. In the present study we illustrate that PKD2 interacts and phosphorylates ABI1 in vitro and in vivo at two potential serine residues. The sites were validated using an antibody that specifically identifies the consensus PKD substrate sequence. Furthermore, PKD2-induced phosphorylation of ABI1 destabilized the interaction between ABI1 and WAVE2 and resulted in relocation of both the proteins from plasma membrane to perinuclear region. Consequences of this destabilization and its potential impact on WAVE2 driven actin polymerization and the associated processes are in the process of investigation. Preliminary results also suggest reduced migration velocity and directedness of a tumor cell. Conclusion: In conclusion, our data demonstrate that ABI1 is a novel substrate of PKD2 that might negatively regulate tumor cell migration via terminating a constitutive interaction between ABI1 and WAVE2. *Impact of ABI1-WAVE2 subcomplex destabilization on WAVE2 induced actin polymerization and lamellipodia extension will be presented at the meeting. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-513. doi:1538-7445.AM2012-LB-513
Successful endoscopic mucosal resection of a solitary extramedullary plasmacytoma in the sigmoid colon
Authors: T. Kodani, T. Osada, T. Terai, T. Ohkusa, T. Shibuya, N. Sakamoto, K. Beppu, J. Kato, A. Nagahara, H. Watanabe, S. Watanabe
Journal: Endoscopy (2011)

A 42-year-old man was referred to our hospital as he was found to be positive for faecal occult blood at a routine checkup. Colonoscopy revealed a submucosal tumor (SMT), 9 mm in size, at the distal end of the sigmoid colon ([Fig. 1]).
Antenatal Glucocorticoids for Late Preterm Birth?
Authors: Caroline A. Crowther, Jane E. Harding
Journal: New England Journal of Medicine (2016)

Late preterm infants (born between 34 weeks and 36 weeks 5 days of gestation) make up the largest proportion of preterm births and are at higher risk for neonatal death and complications including respiratory disease than are infants born at term (at least 37 weeks of gestation).1 Late preterm survivors are also at risk for lifelong health problems, including cerebral palsy and learning difficulties.2 Personal and societal costs of these births are substantial.3A single course of antenatal glucocorticoids given to mothers at risk for preterm birth is now standard prophylactic treatment against the respiratory distress syndrome and other serious . . .
Postprandial versus Preprandial Blood Glucose Monitoring in Women with Gestational Diabetes Mellitus Requiring Insulin Therapy
Authors: Margarita de Veciana, Carol A. Major, Mark A. Morgan, Tamerou Asrat, Julianne S. Toohey, Jean M. Lien, Arthur T. Evans
Journal: New England Journal of Medicine (1995)

The fetuses of women with gestational diabetes mellitus are at risk for macrosomia and its attendant complications. The best method of achieving euglycemia in these women and reducing morbidity in their infants is not known. We compared the efficacy of postprandial and preprandial monitoring in achieving glycemic control in women with gestational diabetes.
Abstract 2131: Functional assays to define agonists and antagonists of sigma-2 receptors.
Authors: Robert H. Mach, Chenbo Zeng, Justin M. Rothfuss, Jun Zhang, Suwanna Vangveravong, Wenhua Chu, Zhude Tu, Shihong Li
Journal: Cancer Research (2013)

Abstract The sigma receptor was originally defined pharmacologically as the specific binding site for a group of compounds named as sigma ligands. The sigma-2 receptor has been identified as a biomarker in proliferating tumors. It regulates cell growth and is an emerging target for cancer diagnosis and therapeutics. Up to date numerous sigma-2 selective ligands have been developed. However, there is no well-established functional assay for defining agonist/antagonist for sigma-2 receptors. Many sigma-2 ligands with diverse structures have been shown to induce cytotoxicity in a variety of cancer cells by triggering caspase-independent and caspase-dependent apoptosis. Therefore, in the current study, we propose to use cell viability and caspase 3 activity, a hallmark of apoptosis, as functional assays to define agonist/antagonist for sigma-2 receptors. Three classes of sigma-2 ligands developed in our laboratory were tested in these two assays in two tumor cell lines: mouse breast cancer cell line EMT6 and human melanoma cell line MDA-MB435. Based on the ratios of the EC50 values of our sigma-2 ligands to the EC50 of siramesine, we categorized the azabicyclononane analogs as agonists (e.g. SV 119) or partial agonists (e.g. WC 26 and SV 95), and benzamide analogs as non-canonical antagonists (e.g. RHM-1) since they do not trigger cell death, and they do not block sigma-2 agonist-induced cell death. SV 95 partially blocked SV 119-induced cytotoxicity. The establishment of functional assays for defining agonist/antagonist will facilitate functional characterization of sigma-2 ligands and sigma-2 receptors. Citation Format: Robert H. Mach, Chenbo Zeng, Justin M. Rothfuss, Jun Zhang, Suwanna Vangveravong, Wenhua Chu, Zhude Tu, Shihong Li. Functional assays to define agonists and antagonists of sigma-2 receptors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2131. doi:10.1158/1538-7445.AM2013-2131
AB0295 Clinical study on etanercept combined with tripterygium wilfordii polyglycoside for treatment of eldly rheumatoid arthritis
Authors: Z. Ye, W. He, Z. Yin, J. Gao, Y. Xie
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate the efficacy and safety of etanercept plus Tripterygium wilfordii polyglycoside(TWP) in <i>elderly</i> patients with active rheumatoid arthritis(RA). <h3>Methods</h3> 46 <i>elderly</i> patients with active RA were randomized to the treatment group ( n = 24) and the control group ( n = 22). The former was treated with ETN ( injected with 50mg/week subcutaneously, after 3 months,25mg/week) along with TWP(10mg, tid) ; the latter was treated with ETN and MTX (10mg/week). The whole course lasted 24 weeks, patients were assessed at weeks 0,2,6,14 and 24. The change from baseline in pain, tender joint count, swollen joint count, health assessment (HAQ), patient's global assessment, physician's global assessment, ESR and CRP were evaluated. The curative effect was statistically evaluated by the United States Institute of Rheumatology ACR 20, ACR50 and ACR70 improvement criteria. Meanwhile adverse events were recorded and evaluated. <h3>Results</h3> At week 2, the ACR20 was achieved in 58% of patients receiving ETN plus TWP, compared with 56% of patients receiving ETN plus MTX(p&gt;0.05). The results for other clinical signs and symptoms and quality of life showed no difference between these two groups(P&gt;0.05). At week 24, the ACR20 improvement was achieved in 80.2% of patients receiving ETN plus TWP, compared with 78% of patients receiving ETN plus MTX(p&gt;0.05). There was no significant difference between the two groups in adverse effects. <h3>Conclusions</h3> These two regimens of ETN plus TWP and ETN plus MTX all can improve the clinical signs and symptoms and quality of life, There was no difference between these two groups in efficacy, and they were well tolerated in the treatment of <i>elderly</i> patients with active RA. <h3>Disclosure of Interest</h3> None Declared
A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer
Authors: Steven M. Keller, Sudeshna Adak, Henry Wagner, Arnold Herskovic, Ritsuko Komaki, Burke J. Brooks, Michael C. Perry, Robert B. Livingston, David H. Johnson
Journal: New England Journal of Medicine (2000)

We conducted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is superior to thoracic radiotherapy alone in prolonging survival and preventing local recurrence in patients with completely resected stage II or IIIa non–small-cell lung cancer.
Drainage of Right Pulmonary Vein into Inferior Vena Cava
Authors: Victor A. McKusick, Robert N. Cooley
Journal: New England Journal of Medicine (1955)

UNTIL recently anomalous drainage of pulmonary veins into the right side of the circulation (anomalous pulmonary venous return, drainage or connection, with transposition of the pulmonary veins) was considered a most unusual condition and one rarely diagnosed in life. With the more extensive practice of angiocardiography and cardiac catheterization the anomaly has been recognized with increasing frequency. Furthermore, clinical and roentgenologic correlations have indicated that in at least some of these cases this malformation can be identified without recourse to these specialized procedures. Also, the possibility of surgical correction1 ,1a has made more purposeful the attempts at an accurate understanding of . . .
Abstract 1184: The circadian factor Period2 modulates p53 function in unstressed cells
Authors: Carla V. Finkielstein, Tetsuya Gotoh, Marian Vila-Caballer, Carlo Santos, Jingjing Liu, Jianhua Yang
Journal: Cancer Research (2012)

Abstract Circadian rhythms are mechanisms that measure time on a scale of about 24 h and that adjusts our body to external environmental signals. Core circadian clock genes are defined as genes whose protein products are necessary components for the generation and regulation of circadian rhythms. Circadian proteins also regulate genes involved in either cell division or death; and a perturbation of the balance among these processes leads to cancer development and progression. A key aspect of cancer research is identifying new regulatory pathways involved in proliferation and differentiation of cell. Disruption of circadian rhythm has recently emerged as a new potential risk factor in the development of cancer, pointing to the core gene period 2 (per2) as a tumor suppressor. However, it remains unclear how the circadian network regulates tumor suppression, nor which, if any, of its components is either the ultimate effector that influences the fate of the cell. Initial experiments were devoted to identify new interacting partners for Per2 using a two-hybrid system. Interestingly, among the positive clones analyzed was the tumor suppressor protein p53. This result was validated by immunoprecipitation of recombinant and endogenous Per2/p53 complexes from unstressed cells. Pull-down assays using tagged-expressed proteins fragments and labeled proteins were later used to map the interacting regions between Per2 and p53. Our results show Per2 binds to the C-terminus of p53 in a region that includes the DNA binding and tetramerization domains and that includes the ubiquitination sites. Thus, we hypothesized that binding of Per2 to p53 might act by blocking Mdm2-mediated ubiquitination of p53 target residues in the C-terminus and therefore altering its stability. We next examined the formation of the Mdm2/p53/Per2 complex by immunoprecipitation. Our data show anti-p53 antibody is able to co-immunoprecipitate Per2 and Mdm2. Moreover, in vitro and in vivo ubiquitination assays show that binding of Per2 to p53 prevented ubiquitination of p53 by Mdm2 without altering their binding. Immunofluorescence studies using H1299 cells (p53-) confirmed Per2 role in p53 stabilization and for localization. Overall our results suggest that Per2 modulates the stability of p53 in unstressed cells, and might be responsible for the oscillatory levels of p53 observed in a 24 h cycle. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1184. doi:1538-7445.AM2012-1184